TransMedics (TMDX) Short term Debt (2025 - 2026)

TransMedics' (TMDX) quarterly Short term Debt came in at $15.0 million in Q1 2026, up 50.0% quarter-over-quarter from $10.0 million in Q4 2025.

TransMedics (TMDX) Short term Debt (2025 - 2026) Analysis & Trends

TransMedics' Short term Debt history runs 2 years deep, the most recent figure standing at $15.0 million for Q1 2026.

On a quarterly basis, Short term Debt changed N/A year-over-year to $15.0 million in Q1 2026; TTM through Mar 2026 was $15.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $10.0 million, changed N/A from the prior year.
Short term Debt grew to $15.0 million in Q1 2026 per TMDX's latest filing, from $10.0 million in the prior quarter.
Across five years, Short term Debt topped out at $15.0 million in Q1 2026 and bottomed at $5.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	TransMedics	2.45 Bn	1.98 Bn	101.16 Mn

Download Data